Design and synthesis of novel oridonin analogues as potent anticancer agents

Qing-Kun Shen, Zheng-Ai Chen, Hong-Jian Zhang, Jia-Li Li, Chuan-Feng Liu, Guo-Hua Gong, and Zhe-Shan Quan

ABSTRACT
To identify anticancer agents with higher potency and lower toxicity, a series of oridonin derivatives with substituted benzene moieties at the C17 position were designed, synthesised, and evaluated for their antiproliferative properties. Most of the derivatives exhibited antiproliferative effects against AGS, MGC803, Bel7402, HCT116, A549, and Hela cells. Compound 2p (IC50 = 1.05 μM) exhibited the most potent antiproliferative activity against HCT116 cells; it was more potent than oridonin (IC50 = 6.84 μM) and 5-fluorouracil (5-FU) (IC50 = 24.80 μM). The IC50 value of 2p in L02 cells was 6.5-fold higher than that in HCT116 cells. Overall, it exhibited better selective antiproliferative activity and specificity than oridonin and 5-FU. Furthermore, compound 2p arrested HCT116 cells at the G2 phase of the cell cycle and increased the percentage of apoptotic cells to a greater extent than oridonin.

Introduction
Over the last several decades, cancer has been one of the leading causes of death in the world. Cytotoxic agents are the mainstay of anticancer therapy. However, due to their inability to differentiate between normal and cancerous cells, they cause severe adverse effects, leading to poor patient compliance. Therefore, the identification of novel anticancer agents with higher potency and lower toxicity is needed for the treatment of aggressive and refractory cancers. More than 60% of all clinically used anticancer drugs originate from natural sources, highlighting the success of natural products.

Oridonin (1) is an ent-kaurane diterpenoid isolated from Isodon rubescens (Donglingcao in Chinese). Since the identification of its antitumour potential in 1967, it has been used in traditional Chinese medicine. It is reported to prevent hepatic fibrosis, Alzheimer’s disease, microbial infections, and inflammation. It has been shown to exert anticancer effects with limited adverse effects. However, limited hydrophobic/hydrophilic partitioning and oral bioavailability diminish its therapeutic potential and clinical utility. Therefore, it is necessary to develop novel oridonin analogues with potent antitumour efficacy through structural effective modifications.

Compounds with substituted benzene rings display a broad spectrum of biological activities; therefore, structural modification by adding substituted benzene rings is widely used in medicinal chemistry. It increases receptor binding by promoting hydrophobic interactions and enhances lipid solubility to facilitate drug permeation. In addition, an arylating ω,β-unsaturated ketone system is commonly present in several anticancer agents, such as compounds 3–5 (Figure 1). In a previous experiment, the arylated ω,β-unsaturated ketone was added to the structure of costunolide; the resultant compound 3 was found to have better antiproliferative activity against A549 cells (IC50 = 15.65 μM) than costunolide (IC50 = 39.80 μM) (Figure 1). This substitution in the D ring was also found to be responsible for the antiproliferative activity of oridonin; the reduction or expansion of this ring is expected to significantly reduce efficacy. Inspired by these reports, we synthesised novel oridonin analogues, containing the arylated ω,β-unsaturated ketone system in its D ring, to evaluate whether these analogues display better anticancer activity than oridonin. In this study, we designed, synthesised, and evaluated novel oridonin derivatives (2a–2y) containing a substituted benzene at the C-17 position (Figure 1) for their in vitro antitumour efficacy.

Materials and methods
Chemistry
IR spectra were recorded (in KBr) on IR Prestige-21. 1H-NMR and 13C-NMR spectra were measured on an AV-300 (Bruker BioSpin, Switzerland), 13C-NMR spectra were measured on an AV-500 (Bruker BioSpin, Switzerland), and all chemical shifts were given in ppm relative to tetramethylsilane (TMS). High-resolution mass spectra were measured using a matrix-assisted laser desorption/ionisation-time of flight (TOF)/TOF mass spectrometer (Bruker Daltonik, Bremen, Germany). The major chemicals were purchased from Aldrich Chemical Corporation. All other chemicals were of analytical grade.
General procedure for the synthesis of compound (2a–2y)

To a stirred solution of oridonin (0.19 mmol, 70.00 mg), substituted iodobenzene (0.23 mmol) in N, N-dimethylformamide (5.00 ml), triethylamine (0.58 mmol, 58.18 mg), palladium acetate (0.01 mmol, 2.24 mg) and triphenylphosphine (0.020 mmol, 5.24 mg) was added. The reaction mixture was stirred at 90 °C for 20–24 h monitored by TLC and then concentrated under reduced pressure. The residue was added water (10.0 ml) and extracted with dichloromethane. The organic layer was washed with saturated NaHCO₃, saturated NaCl and several portions of 15% hydrochloric acid solution, and dried over anhydrous Na₂SO₄.

Yield 70%. ¹H-NMR (DMSO-d₆, 300 MHz): δ 1.02 (s, 3H, −CH₃), 1.04 (s, 3H, −CH₃), 1.16–1.35 (m, 4H), 1.40–1.69 (m, 4H), 1.79–1.85 (m, 1H), 2.10–2.20 (m, 1H), 2.56–2.65 (m, 1H), 3.27–3.30 (m, 1H), 3.52–3.58 (m, 1H), 3.88 (d, 1H, J = 9.9 Hz), 4.15 (d, 1H, J = 9.6 Hz), 4.40 (d, 1H, J = 5.1 Hz), 4.86 (s, 1H), 6.03 (s, 1H), 6.24 (d, 1H, J = 10.5 Hz), 6.90 (s, 1H), 7.42 (s, 1H), 7.46–7.61 (m, 5H). ¹³C-NMR (DMSO-d₆, 125 MHz): δ 19.89, 22.19, 28.44, 29.84, 33.21, 33.85, 38.87, 40.96, 41.37, 53.28, 60.04, 61.46, 63.25, 72.16, 73.47, 73.67, 97.54, 129.54, 130.35, 130.67, 133.19, 134.74, 143.63, 209.50. IR (KBr) cm⁻¹: 3394, 2912, 1693, 1615. HRMS calcd. for C₂₆H₃₂NaO₆ ([M + Na]⁺): 463.2091; found: 463.2085.

(15,4aR,5S,6S,6aR,9S,11aS,14R,E)-8-(3-fluorobenzylidene)-1,5,6,14-tetrahydroxy-4,4-dimethyldecahydro-1H-6,11b-(epoxymethano)-6a,9-methanoctyclohepta[a]naphthalene-7(8H)-one (2b)

Yield 43%. ¹H-NMR (DMSO-d₆, 300 MHz): δ 1.01 (s, 3H, −CH₃), 1.03 (s, 3H, −CH₃), 1.15–1.35 (m, 4H), 1.43–1.67 (m, 4H), 1.79–1.83 (m, 1H), 2.12–2.20 (m, 1H), 2.57–2.67 (m, 1H), 3.27–3.30 (m, 1H), 3.52–3.58 (m, 1H), 3.88 (d, 1H, J = 9.9 Hz), 4.15 (d, 1H, J = 9.6 Hz), 4.41 (d, 1H, J = 5.1 Hz), 4.86 (s, 1H), 6.03 (s, 1H), 6.15 (d, 1H, J = 10.5 Hz), 6.91 (s, 1H), 7.29–7.59 (m, 5H). ¹³C-NMR (DMSO-d₆, 125 MHz): δ 19.85, 22.17, 28.39, 29.81, 33.19, 33.84, 40.97, 41.33, 53.34, 60.01, 61.53, 63.27, 72.17, 73.39, 73.67, 97.50, 117.05, 126.56, 131.56, 137.15, 144.98, 161.77, 163.71, 209.43. IR (KBr) cm⁻¹: 3404, 2902, 1695, 1618. HRMS calcd. for C₂₆H₃₁FNaO₆ ([M + Na]⁺): 481.1997; found: 481.1989.

(15,4aR,5S,6S,6aR,9S,11aS,14R,E)-8-(4-fluorobenzylidene)-1,5,6,14-tetrahydroxy-4,4-dimethyldecahydro-1H-6,11b-(epoxymethano)-6a,9-methanoctyclohepta[a]naphthalene-7(8H)-one (2c)

Yield 46%. ¹H-NMR (DMSO-d₆, 300 MHz): δ 1.01 (s, 3H, −CH₃), 1.03 (s, 3H, −CH₃), 1.14–1.34 (m, 4H), 1.43–1.66 (m, 4H), 1.80–1.82 (m, 1H), 2.12–2.20 (m, 1H), 2.57–2.67 (m, 1H), 3.27–3.30 (m, 1H), 3.52–3.58 (m, 1H), 3.88 (d, 1H, J = 9.9 Hz), 4.15 (d, 1H, J = 9.6 Hz), 4.41 (d, 1H, J = 5.1 Hz), 4.86 (s, 1H), 6.03 (s, 1H), 6.15 (d, 1H, J = 10.5 Hz), 6.91 (s, 1H), 7.29–7.59 (m, 5H). ¹³C-NMR (DMSO-d₆, 125 MHz): δ 19.85, 22.17, 28.39, 29.81, 33.19, 33.84, 40.97, 41.33, 53.34, 60.01, 61.53, 63.27, 72.17, 73.39, 73.67, 97.50, 117.05, 126.56, 131.56, 137.15, 144.98, 161.77, 163.71, 209.43. IR (KBr) cm⁻¹: 3404, 2902, 1695, 1618. HRMS calcd. for C₂₆H₃₁FNaO₆ ([M + Na]⁺): 481.1997; found: 481.1989.
6.20 (d, 1H, J = 9.9 Hz), 4.14 (d, 1H, J = 9.6 Hz), 4.40 (d, 1H, J = 5.1 Hz), 4.86 (s, 1H), 6.02 (s, 1H), 6.18 (d, 1H, J = 10.5 Hz), 6.90 (s, 1H), 7.29 (s, 1H), 7.39 (s, 4H). IR (KBr) cm⁻¹: 3434, 2933, 1675, 1627. IR (KBr) cm⁻¹: 3429, 2921, 1684, 1620. HRMS calcd. for C₂₃H₂₃Na₉O₆ ([M + Na]⁺): 477.2248; found: 477.2236.

(15a,4aR,5S,6S,6aR,9S,11aS,14R,E)-1,5,6,14-tetrahydroxy-4,4-dimethyl-8-(3-methoxybenzylidene)decahydro-1H-6,11b-(epoxymethano)-6a,9-methanocyclohepta[a]naphthalen-7(8H)-one (2f)

Yield 72%. ¹H-NMR (DMSO-d₆, 300 MHz): δ 1.01 (s, 3H, –CH₃), 1.04 (s, 3H, –CH₃), 1.14–1.34 (m, 4H), 1.43–1.64 (m, 4H), 1.76–1.80 (m, 1H), 2.12–2.19 (m, 1H), 2.27 (s, 6H), 2.57–2.65 (m, 1H), 3.27–3.30 (m, 1H), 3.51–3.57 (m, 1H), 3.87 (d, 1H, J = 5.1 Hz), 4.14 (d, 1H, J = 9.9 Hz), 4.38 (d, 1H, J = 5.1 Hz), 4.85 (s, 1H), 6.02 (s, 1H), 6.20 (d, 1H, J = 10.5 Hz), 6.85 (s, 1H), 7.32–7.34 (m, 3H), 7.39 (d, 1H, J = 7.0 Hz), 7.58 (s, 1H). ¹³C-NMR (DMSO-d₆, 125 MHz): δ 19.93, 20.06, 22.15, 28.99, 29.83, 33.18, 33.86, 38.88, 40.94, 40.99, 53.42, 60.13, 61.64, 63.27, 72.15, 73.41, 76.54, 126.80, 126.83, 130.09, 130.21, 131.20, 133.54, 138.87, 144.18, 209.55. IR (KBr) cm⁻¹: 3405, 2925, 1674, 1632. HRMS calcd. for C₂₉H₂₉NaO₆ ([M + Na]⁺): 491.2404; found: 491.2396.

(15a,4aR,5S,6S,6aR,9S,11aS,14R,E)-1,5,6,14-tetrahydroxy-4,4-dimethyl-8-(3-methoxybenzylidene)decahydro-1H-6,11b-(epoxymethano)-6a,9-methanocyclohepta[a]naphthalen-7(8H)-one (2g)

Yield 67%. ¹H-NMR (DMSO-d₆, 300 MHz): δ 1.01 (s, 3H, –CH₃), 1.04 (s, 3H, –CH₃), 1.17–1.31 (m, 4H), 1.44–1.67 (m, 4H), 1.78–1.83 (m, 1H), 2.12–2.21 (m, 1H), 2.37 (s, 3H), 2.59–2.65 (m, 1H), 3.27–3.30 (m, 1H), 3.52–3.57 (m, 1H), 3.87 (d, 1H, J = 9.9 Hz), 4.14 (d, 1H, J = 9.6 Hz), 4.40 (d, 1H, J = 5.1 Hz), 4.86 (s, 1H), 6.02 (s, 1H), 6.18 (d, 1H, J = 10.5 Hz), 6.90 (s, 1H), 7.29 (s, 1H), 7.39 (s, 4H). ¹³C-NMR (DMSO-d₆, 125 MHz): δ 19.88, 21.45, 22.18, 28.46, 29.83, 33.20, 33.84, 38.86, 40.95, 41.39, 53.28, 55.28, 60.03, 63.25, 72.17, 73.46, 76.73, 97.54, 127.65, 129.43, 131.08, 131.34, 134.32, 134.69, 138.76, 143.46, 209.49. IR (KBr) cm⁻¹: 3434, 2933, 1675, 1627. IR (KBr) cm⁻¹: 3429, 2921, 1684, 1620. HRMS calcd. for C₂₉H₂₉NaO₆ ([M + Na]⁺): 477.2248; found: 477.2236.
(15,4aR,5S,6S,6aR,9S,11aS,14R,E)-1,5,6,14-tetrahydroxy-4,4-dimethyl-8-(3,4,5-trimethoxybenzyliden)e-decahydro-1H-6,11b-(epoxymethano)-6a,9-methanocyclohepta[a]naphthalen-7(8H)-one (2n)

Yield 87%. 1H-NMR (DMSO-d6, 300 MHz): δ 1.02 (s, 3H, -CH3), 1.04 (s, 3H, -CH3), 1.15–1.35 (m, 4H), 1.47–1.64 (m, 4H), 1.78–1.82 (m, 1H), 2.08–2.19 (m, 1H), 2.55–2.63 (m, 1H), 3.35–3.37 (m, 1H), 3.52–3.57 (m, 1H), 3.72 (s, 3H, -OCH3), 3.83 (s, 6H, -OCH3), 3.89 (s, 1H, J = 9.9 Hz), 4.14 (s, 1H, J = 9.6 Hz), 4.39 (d, 1H, J = 5.1 Hz), 4.85 (s, 1H), 5.98 (s, 1H), 6.28 (d, 1H, J = 10.5 Hz), 6.69 (s, 1H), 7.38 (s, 1H). 13C-NMR (DMSO-d6, 125 MHz): δ 19.88, 22.21, 28.21, 29.84, 33.23, 38.85, 40.95, 41.45, 53.24, 56.38, 59.97, 60.04, 61.42, 63.25, 71.72, 73.46, 73.68, 79.56, 108.10, 130.23, 133.62, 139.57, 142.60, 153.46, 209.29. IR (KBr) cm⁻¹: 3390, 2923, 1675, 1616. HRMS calcd. for C_{28}H_{38}NaO_{8} ([M + Na]⁺): 553.2408; found: 553.2398.

(15,4aR,5S,6S,6aR,9S,11aS,14R,E)-1,5,6,14-tetrahydroxy-4,4-dimethyl-8-(4-propoxybenzylidene)decahydro-1H-6,11b-(epoxymethano)-6a,9-methanocyclohepta[a]naphthalen-7(8H)-one (2o)

Yield 85%. 1H-NMR (DMSO-d6, 300 MHz): δ 0.98–1.03 (m, 9H, -CH3), 1.15–1.34 (m, 6H), 1.47–1.64 (m, 4H), 1.73–1.78 (m, 2H), 2.08–2.20 (m, 1H), 2.57–2.65 (m, 1H), 3.25–3.28 (m, 1H), 3.50–3.55 (m, 1H), 3.87 (d, 1H, J = 9.9 Hz), 4.00 (t, 2H, J = 6.0 Hz), 4.13 (d, 1H, J = 9.6 Hz), 4.40 (d, 1H, J = 5.1 Hz), 4.83 (s, 1H), 6.02 (s, 1H), 6.37 (d, 1H, J = 10.5 Hz), 6.90 (s, 1H), 7.05 (d, 2H, J = 8.1 Hz), 7.55 (d, 2H, J = 8.1 Hz). 13C-NMR (DMSO-d6, 125 MHz): δ 10.80, 19.01, 19.88, 22.18, 22.40, 28.14, 29.84, 33.21, 33.84, 40.95, 41.31, 53.16, 56.51, 60.09, 61.30, 63.22, 69.66, 72.19, 73.66, 79.58, 115.56, 127.12, 132.66, 133.34, 140.74, 160.62, 209.28. IR (KBr) cm⁻¹: 3341, 2936, 1678, 1626. HRMS calcd. for C_{29}H_{38}NaO_{8} ([M + Na]⁺): 521.2510; found: 521.2501.

(15,4aR,5S,6S,6aR,9S,11aS,14R,E)-1,5,6,14-tetrahydroxy-4,4-dimethyl-8-(3-methylbut-2-enyl)oxy)benzylidene)decahydro-1H-6,11b-(epoxymethano)-6a,9-methanocyclohepta[a]naphthalen-7(8H)-one (2p)

Yield 72%. 1H-NMR (DMSO-d6, 300 MHz): δ 1.00 (s, 3H, -CH3), 1.03 (s, 3H, -CH3), 1.13–1.29 (m, 4H), 1.43–1.63 (m, 4H), 1.72 (s, 3H, -CH3), 1.75 (s, 3H, -CH3), 1.79–1.83 (m, 1H), 2.07–2.25 (m, 1H), 2.55–2.66 (m, 1H), 3.25–3.28 (m, 1H), 3.50–3.55 (m, 1H), 3.86 (d, 1H, J = 9.9 Hz), 4.13 (d, 1H, J = 9.6 Hz), 4.40 (d, 1H, J = 5.1 Hz), 4.59 (d, 2H, J = 6.3 Hz, -OCH2-), 4.83 (s, 1H), 5.44 (t, 1H, J = 6.0 Hz), 6.02 (s, 1H), 6.37 (d, 1H, J = 10.5 Hz), 6.90 (s, 1H), 7.05 (d, 2H, J = 8.4 Hz), 7.37 (d, 1H, J = 5.4 Hz), 7.54 (d, 2H, J = 8.4 Hz). 13C-NMR (DMSO-d6, 125 MHz): δ 18.51, 19.01, 19.89, 22.18, 25.28, 28.14, 29.84, 33.21, 33.84, 38.89, 40.94, 41.30, 53.16, 56.51, 60.09, 61.30, 63.22, 69.62, 72.19, 73.66, 79.58, 115.74, 116.99, 127.14, 132.61, 138.11, 140.75, 160.40, 209.29. IR (KBr) cm⁻¹: 3343, 2927, 1674, 1628. HRMS calcd. for C_{31}H_{30}NaO_{8} ([M + Na]⁺): 547.2666; found: 547.2655.

(15,4aR,5S,6S,6aR,9S,11aS,14R,E)-1,5,6,14-tetrahydroxy-4,4-dimethyl-8-(3-[(3-methylbut-2-enyl)oxy)benzylidene)decahydro-1H-6,11b-(epoxymethano)-6a,9-methanocyclohepta[a]naphthalen-7(8H)-one (2q)

Yield 65%. 1H-NMR (DMSO-d6, 300 MHz): δ 1.02 (s, 3H, -CH3), 1.04 (s, 3H, -CH3), 1.15–1.30 (m, 4H), 1.44–1.61 (m, 5H), 1.72 (s, 3H, -CH3), 1.76 (s, 3H, -CH3), 1.81–1.84 (m, 1H), 2.08–2.20 (m, 1H),
(15,4aR,5S,6aR,9S,9aS,14S)-E-8-(4-((R)-3,6-dimethylhepta-2,5-dienyl)oxy)benzylidene)-1,5,6,14-tetrahydroxy-4,4-dimethyldecahydro-1H-6,11b-(epoxymethano)-6a,9-methanocyclohepta[a]naphthalen-7(8H)-one (2r)

N-(4-((E)-(15,4aR,5S,6aR,9S,9aS,14S)-1,5,6,14-tetrahydroxy-4,4-dimethyl-7-oxodecahydro-1H-6,11b-(epoxymethano)-6a,9-methanocyclohepta[a]naphthalen-7(8H)-ylidene)methyl)phthalimidylacetamide (2t)

N-(4-((E)-(15,4aR,5S,6aR,9S,9aS,14S)-1,5,6,14-tetrahydroxy-4,4-dimethyl-7-oxodecahydro-1H-6,11b-(epoxymethano)-6a,9-methanocyclohepta[a]naphthalen-7(8H)-ylidene)methyl)phenylbenzamide (2u)

N-(4-((E)-(15,4aR,5S,6aR,9S,9aS,14S)-1,5,6,14-tetrahydroxy-4,4-dimethyl-7-oxodecahydro-1H-6,11b-(epoxymethano)-6a,9-methanocyclohepta[a]naphthalen-7(8H)-one (2v)

N-(4-((E)-(15,4aR,5S,6aR,9S,9aS,14S)-1,5,6,14-tetrahydroxy-4,4-dimethyl-7-oxodecahydro-1H-6,11b-(epoxymethano)-6a,9-methanocyclohepta[a]naphthalen-7(8H)-one (2w)


\[ (15,4aR,5S,6S,6aR,9S,11aS,14RE)\cdot 1,5,6,14-tetrahydroxy-8-(4-hydroxybenzylidene)-4,4-dimethyldicarboxy-1H-6,11b-(epoxymethano)-6a,9-methanocyclohepta[a]naphthalen-7(8H)-one \ (2x) \]

Yield 80%. $^1$H-NMR (DMSO-d$_6$, 300 MHz): $\delta$ 0.10 (s, 3H, –CH$_3$), 1.03 (s, 3H, –CH$_3$), 1.19–1.35 (m, 4H), 1.44–1.66 (m, 4H), 1.87–1.91 (m, 1H), 2.08–2.32 (m, 1H), 2.55–2.63 (m, 1H), 3.19–3.23 (m, 1H), 3.53–3.58 (m, 1H), 3.88 (d, 1H, $J = 9.9$ Hz), 4.15 (d, 1H, $J = 9.6$ Hz), 4.43 (d, 1H, $J = 5.1$ Hz), 4.88 (s, 1H), 6.07 (s, 1H), 6.26 (d, 1H, $J = 10.5$ Hz), 6.90 (s, 1H), 7.62–7.64 (m, 4H), 8.01–8.05 (m, 2H), 8.14 (s, 2H). $^{13}$C-NMR (DMSO-d$_6$, 125 MHz): $\delta$ 19.00, 19.95, 22.13, 29.18, 29.82, 33.16, 33.87, 38.87, 40.97, 41.29, 53.53, 56.51, 60.17, 61.89, 63.30, 72.17, 74.65, 97.56, 123.97, 126.09, 126.95, 127.26, 127.63, 129.28, 130.49, 131.38, 131.98, 133.74, 145.85, 209.36. IR (KBr) cm$^{-1}$: 3332, 2937, 1668, 1625. HRMS calcd. for C$_{30}$H$_{34}$NaO$_6$ ([M + Na]$^+$): 513.2248; found: 513.2240.

### Biological evaluation

#### Materials

3-[4-(5-Dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) was purchased from Sigma Chemical Co. (St. Louis, MO). The propidium iodide (PI) and Annexin V-FITC apoptosis detection kit was purchased from BD Pharamingen (SanDiego, CA).

#### Cell lines and cell culture

Human gastric cancer (AGS), human differentiation of advanced gastric cancer (MGC803), human colorectal cancer (HCT116), human lung cancer (A549), human hepatocellular carcinoma (BEL7402) and human cervical cancer (HeLa) cell lines were purchased from BD Pharmingen (SanDiego, CA).

### Determination of anticancer activity in vitro

All six human cancer cell lines and normal L02 cells were seeded in 96-well plates at the appropriate densities to ensure exponential growth throughout the experimental period (9 x 10$^3$ cells per well) and then allowed to adhere for 24 h. The cells were then treated for 48 h with four serial dilutions (100, 50, 10, and 1 µM) of each compound. 5-Fluorouracil (5-FU) was used as the positive control. After incubation for 48 h, 10 µM MTT solution was added to each well to give a final concentration of 2 mg ml$^{-1}$. The plates were then incubated for further 4 h. After incubation, the MTT solution was removed and 150 µl DMSO was added to each well to solubilise the formed product. To ensure complete solubilisation, the plates were shaken vigorously for 10 min at room temperature. The absorbance (OD) was read on a microplate reader (ELx800, BioTek, Highland Park, Winooski, VT) at a wavelength of 492 nm and the data were subsequently analysed. The percentage of cell growth inhibition was calculated from the following equation: inhibitory rate (%) = [1 – (OD treated–OD blank)/(OD control–OD blank)] x 100.

### Results and discussion

#### Chemistry

As shown in Scheme 1, oridonin (1) was coupled with different aryl halides under standard Heck reaction conditions [5 mol% Pd(OAc)$_2$, 10 mol% PPh$_3$, NEt$_3$, DMF, 90 ˚C]. The reaction proceeded smoothly at the alkoxy-unsaturated ketone system of oridonin (1) to specifically yield E-olefin products (2a–2y). Before biological evaluation, the compounds were characterised via IR, $^1$H-NMR, and $^{13}$C-NMR spectrometry as well as high-resolution mass spectrometry.

### Biological evaluation

#### MTT assay and structure-activity relationship (SAR) studies

Antiproliferative activities of the synthesised compounds were evaluated against six human cancer cell lines (AGS, MGC803,
Scheme 1. Heck reaction of oridonin with aryl iodides.

Table 1. Antiproliferative efficacy of oridonin derivatives of 2a–2y in six human cancer cell linesb.

| Compound | AGS | MGC803 | Bel7402 | HCT116 | AS49 | Hela |
|----------|-----|--------|---------|--------|------|------|
| 2a       | >100| 9.13 ± 0.82 | 4.97 ± 0.56 | 47.12 ± 4.32 | >100 | >100 |
| 2b       | 13.86 ± 1.50 | 23.63 ± 1.48 | >100 | 36.55 ± 2.43 | 47.43 ± 3.49 | >100 |
| 2c       | 14.35 ± 2.43 | >100 | 12.60 ± 1.05 | 10.25 ± 1.12 | 59.58 ± 4.75 | >100 |
| 2d       | 14.13 ± 1.65 | 2.13 ± 0.13 | 16.94 ± 1.30 | 19.78 ± 3.19 | 12.73 ± 1.56 | 15.19 ± 1.47 |
| 2e       | 15.35 ± 1.78 | 7.27 ± 0.74 | 9.66 ± 1.15 | 13.95 ± 1.94 | 23.08 ± 3.63 | >100 |
| 2f       | >100 | 22.77 ± 1.25 | >100 | 59.03 ± 3.37 | >100 | >100 |
| 2g       | 10.83 ± 2.39 | 17.65 ± 1.13 | 24.22 ± 2.27 | 14.16 ± 1.31 | 66.89 ± 5.29 | 22.32 ± 1.92 |
| 2h       | 5.26 ± 1.09 | 27.20 ± 2.38 | 11.29 ± 0.98 | 10.10 ± 1.39 | 18.04 ± 1.49 | 28.74 ± 2.13 |
| 2i       | 4.79 ± 0.94 | 11.51 ± 1.05 | 8.62 ± 0.78 | 8.03 ± 1.09 | >100 | 14.33 ± 1.16 |
| 2j       | 2.87 ± 0.58 | 10.4 ± 1.29 | 3.56 ± 0.52 | 5.48 ± 0.64 | 7.89 ± 0.99 | 24.72 ± 2.08 |
| 2k       | 2.91 ± 0.42 | 2.79 ± 0.38 | 4.52 ± 0.46 | 2.99 ± 0.32 | 16.79 ± 2.51 | 68.81 ± 5.32 |
| 2l       | 5.85 ± 1.55 | 3.49 ± 0.44 | 2.41 ± 0.37 | 2.28 ± 0.54 | 5.12 ± 0.49 | 14.29 ± 2.04 |
| 2m       | 17.64 ± 2.32 | 17.68 ± 1.67 | 3.15 ± 0.64 | 11.07 ± 1.83 | 13.60 ± 1.89 | 30.66 ± 2.90 |
| 2n       | 17.30 ± 2.41 | 27.96 ± 1.73 | 14.56 ± 1.21 | 18.64 ± 1.78 | 15.78 ± 1.47 | 8.89 ± 0.94 |
| 2o       | 10.01 ± 1.88 | 10.86 ± 1.39 | 6.54 ± 0.94 | 3.09 ± 0.41 | 15.29 ± 1.31 | 8.21 ± 1.20 |
| 2p       | 4.09 ± 0.65 | 4.54 ± 0.94 | 3.21 ± 0.58 | 1.05 ± 0.23 | 5.90 ± 0.52 | 6.33 ± 0.96 |
| 2q       | 3.10 ± 0.41 | 9.10 ± 1.72 | 8.62 ± 1.12 | 7.63 ± 0.81 | 4.66 ± 0.30 | 5.43 ± 0.85 |
| 2r       | 13.7 ± 2.63 | 6.86 ± 1.24 | 8.45 ± 1.32 | 2.39 ± 0.19 | 4.16 ± 0.45 | 9.85 ± 2.03 |
| 2s       | 51.03 ± 3.34 | 53.22 ± 4.05 | 7.00 ± 1.05 | 10.04 ± 1.13 | 99.8 ± 7.45 | >100 |
| 2t       | 22.05 ± 1.04 | 10.04 ± 0.84 | 14.56 ± 1.66 | 47.9 ± 3.91 | 97.1 ± 5.93 | >100 |
| 2u       | 12.03 ± 1.99 | 12.22 ± 0.94 | 7.35 ± 1.28 | 4.02 ± 0.33 | 21.48 ± 1.88 | 9.79 ± 1.08 |
| 2v       | 30.28 ± 2.24 | 32.86 ± 2.31 | 60.32 ± 4.14 | 28.17 ± 2.67 | >100 | >100 |
| 2w       | >100 | >100 | >100 | 22.14 ± 3.28 | >100 | >100 |
| 2x       | >100 | >100 | >100 | 30.12 ± 3.57 | >100 | >100 |
| 2y       | 55.04 ± 4.43 | 20.96 ± 1.24 | 51.21 ± 5.43 | 17.46 ± 1.44 | 12.6 ± 1.39 | 26.02 ± 1.48 |
| Oridonin | 8.35 ± 0.41 | 9.18 ± 1.01 | 9.59 ± 1.19 | 6.84 ± 0.98 | 24.66 ± 2.11 | 15.03 ± 2.01 |
| 5-FU     | 29.61 ± 3.40 | 30.52 ± 4.42 | 21.3 ± 2.43 | 24.80 ± 2.08 | 23.65 ± 3.14 | 34.61 ± 3.14 |

aIC50: concentration that inhibits 50% of cell growth.
bMTT methods; cells were incubated with indicated compounds for 48 h (means ± SD, n = 3).
Bel7402, HCT116, A549, and HeLa) and compared with those of oridonin and 5-FU. The MTT assay was performed using a standard protocol.

The results of this screening are summarised in Table 1. Most of the tested compounds exhibited similar or better bioactivities in vitro than 5-FU. Among them, five alkoxyphenyl-substituted compounds (2j, 2k, 2l, 2p, and 2q) and two methylphenyl substituted compounds (2h and 2i) displayed lower IC₅₀ values (2.87–5.26 μM) than oridonin (8.35 μM) in human gastric cancer cells (AGS). The order of antitumour activity was o-OCH₃ > p-OCH₃ > m-isopentenylxy > 2,4-CH₃ > p-CH₃.

Table 2. In vitro antiproliferative activities of compounds 2l and 2p against normal cell line (L02).

| Compound | (IC₅₀, μM) | L02 | AGS | MGC803 | Bel7402 | HCT116 | A549 | Hela |
|----------|------------|-----|-----|--------|---------|--------|------|------|
| 2l       | 7.15 ± 1.36| 1.22| 2.05| 2.97   | 3.14    | 1.40   | 0.44 |
| 2p       | 6.88 ± 1.12| 3.28| 0.75| 0.72   | 6.55    | 1.17   | 1.09 |
| Oridonin | 6.97 ± 0.98| 0.83| 0.76| 0.73   | 1.02    | 0.28   | 0.46 |
| 5-FU     | 19.12 ± 1.01| 0.65| 0.63| 0.90   | 0.65    | 0.81   | 0.55 |

aIC₅₀: concentration that inhibits 50% of cell growth. bSelectivity index (IC₅₀ on normal cells/IC₅₀ on tumour cells).

Overall, 14 compounds (2d, 2e, 2h, 2j–2r, 2u, and 2y) showed more potent antiproliferative activities than oridonin (IC₅₀ = 24.66 μM) in human lung cancer cells (A549); compound 2r was the most potent with an IC₅₀ value of 4.16 μM. Compounds 2l, 2n–2r, and 2u against human cervical cancer cells (HeLa) exhibited better antiproliferative activities (IC₅₀ = 14.33, 8.89, 8.21, 6.33, 5.43, and 9.85 μM, respectively) than oridonin (IC₅₀ = 15.03 μM). Overall, compounds 2l (2,4-CH₃) and 2p (p-isopentenylxy) showed more potent antiproliferative activities in vitro than oridonin against all the six cancer cell lines. Remarkably, compound 2p was 6.8-fold more active than oridonin,
inhibiting HCT116 cell proliferation with an IC₅₀ value of 1.05 μM. However, three phenol-substituted compounds (2v, 2w, and 2x) and two aminophenyl-substituted compounds (2s and 2t) displayed poor antiproliferative activities against the six tumour cell lines.

Based on these preliminary results, we identified the following structure-activity relationships: (1) the introduction of benzene with hydrophobic groups, such as alkoxy, methyl, and halogen, at the C17 position of oridonin, significantly improves antitumour activity with the order of positive potency as alkoxy > methyl > halogen; and (2) the introduction of benzene with hydrophilic groups, such as –OH and –NH₂, reduces the antitumour activity of oridonin. Based on this interpretation, we suspected that the lipid partition coefficient crucially affects the antitumour activity of oridonin derivatives.

Selective inhibition of cancer cell growth by compounds 2l and 2q
Lack of selective cytotoxicity is the main factor that restricts the dose of most conventional chemotherapeutic agents. We compared the toxicity of compounds 2l and 2p with oridonin or 5-FU on human normal liver cells (L-02). Selectivity indexes between cancer cells and L-02 cells were calculated. As shown in Table 2, compound 2p exhibited 6.5-fold higher selectivity for HCT116 cells than for normal L-02 cells; this selectivity displayed by 2p was significantly higher than that displayed by oridonin. Therefore, compound 2p was further analysed to identify its mechanism of selective cytotoxicity.

**Cell cycle regulation by compound 2p**
Numerous cytotoxic compounds exert their antiproliferative effect by inducing cell cycle arrest (at a particular cell cycle checkpoint), apoptosis, or both. These mechanisms are considered to be effective anticancer strategies. We used fluorescence-activated cell sorting analysis to explore the mechanism by which compound 2p reduced the viability of HCT116 cells. Compound 2p and oridonin were selected and tested against HCT116 cell lines at a concentration of 5 μM. As shown in Figure 2, compound 2p significantly increased the percentage of G2 cell population from 19.35 to 41.46% after 48 h of incubation, whereas oridonin increased it to 37.80%. This finding suggests that compound 2p induces cell cycle arrest at the G2 phase.

**Apoptotic effects of compound 2p**
Because compound 2p arrested the cells in the G2 phase, we investigated whether it also causes apoptosis. HCT116 cells were treated with the vehicle, compound 2p (5 μM), or oridonin (5 μM) for 48 h, and then stained with annexin V-FITC and PI. As shown in Figure 3, the percentage of total apoptotic cells (right quadrants, Q₂ + Q₃) increased to 60.94% after treatment with compound 2p.
whereas it was 24.84% after oridonin treatment; vehicle treatment induced apoptosis in 6.20% of the cells. This result indicated that compound 2p is a more potent inducer of apoptosis than oridonin.

**Conclusion**

A series of oridonin derivatives with substituted benzene analogues at the C17 position were designed, synthesised, and evaluated for their antiproliferative properties against six human cancer cell lines (AGS, MGC803, Bel7402, HCT116, A549, and HeLa), and the noncancerous human L02 cells. Most of the synthesised oridonin derivatives displayed significant antiproliferative effects in these cancer cell lines. SAR analysis indicated that the alkoxyphenyl ring at the C17 position of oridonin effectively improves its antitumour efficacy. Compound 2p possessed the highest antiproliferative activity against HCT116 cells; it was 6.8-fold more potent than oridonin. The IC50 value of 2p in L02 cells was 6.5-fold higher than that in HCT116 cells, indicating that it exhibits selective antiproliferative effects.

In addition, cell cycle analysis revealed that compound 2p arrested HCT116 cells at the G2 phase. It increased the percentage of apoptotic cells to a greater extent than oridonin. Therefore, compound 2p could serve as a promising lead candidate for further studies.

**Disclosure statement**

The authors declare no conflict of interest.

**Funding**

This work was supported by the National Natural Science Foundation of China (No. 21662036, 81660837).

**References**

1. Mahapatra DK, Bharti SK, Asati V. Anti-cancer chalcones: structural and molecular target perspectives. Eur J Med Chem 2015;98:69–114.
2. Bray F, Møller B. Predicting the future burden of cancer. Nat Rev Cancer 2006;6:63–74.
3. Cragg GM, Newman DJ. Nature: a vital source of leads for anticancer drug development. Phytochem Rev 2009;8:313–31.
4. Fujita E, Nagao Y, Kaneko K, et al. The antitumor and antibacterial activity of the isodon diterpenoids. Chem Pharm Bull (Tokyo) 1976; 24:2118–27.
5. Bohanon FJ, Wang XF, Ding CY, et al. Oridonin inhibits hepatic stellate cell proliferation and fibrogenesis. J Surg Res 2014;190:55–63.
6. Bohanon FJ, Wang XF, Graham BM, et al. Enhanced effects of novel oridonin analog CYD0682 for hepatic fibrosis. J Surg Res 2015;199:441–9.
7. Bohanon FJ, Wang XF, Graham BM, et al. Enhanced anti-fibrogenic effects of novel oridonin derivative CYD0692 for hepatic stellate cells. Mol Cell Biochem 2015;410:293–300.
8. Wang SL, Yang H, Yu LJ, et al. Oridonin attenuates Aβ1-42 induced neuroinflammation and inhibits NF-κB pathway. PLoS One 2014;9:e104745.
9. Xu ST, Pei LL, Li DH, et al. Synthesis and anti-mycobacterial evaluation of natural oridonin and its enmein-type derivatives. Fitoterapia 2014;99:300–6.
10. Ku CM, Lin JY. Anti-inflammatory effects of 27 selected terpenoid compounds tested through modulating Th1/Th2 cytokine secretion profiles using murine primary splenocytes. Food Chem 2013;141:1104–13.
11. Xu ST, Yao H, Luo SS, et al. A novel potent anticancer compound optimized from a natural oridonin scaffold induces apoptosis and cell cycle arrest through the mitochondrial pathway. J Med Chem 2017;60:1449–68.
12. Ding CY, Zhang YS, Chen HJ, et al. Oridonin ring A-based diverse constructions of enone functionality: identification of novel dienone analogues effective for highly aggressive breast cancer by inducing apoptosis. J Med Chem 2013;56:8814–25.
13. Xu ST, Pei LL, Wang CQ, et al. Novel hybrids of natural oridonin-bearing nitrogen mustards as potential anticancer drug candidates. ACS Med Chem Lett 2014;5:797–802.
14. Li DH, Han T, Tian HT, et al. Novel nitric oxide-releasing spiro-lactone-type diterpenoid derivatives with in vitro synergistic anticancer activity as apoptosis inducer. Bioorg Med Chem Lett 2016;26:4191–6.
15. Li DH, Xu ST, Cai H, et al. Enmein-type diterpenoid analogs from natural kaurene-type oridonin: synthesis and their antitumor biological evaluation. Eur J Med Chem 2013;64:215–21.
16. Ding CY, Wang LL, Chen HJ, et al. ent-Kaurane-based regio-and stereoselective inverse electron demand hetero-Diels-Alder reactions: synthesis of dihydropyran-fused diterpenoids. Org Biomol Chem 2014;12:8442.
17. Li DH, Xu ST, Cai H, et al. Library construction and biological evaluation of enmein-type diterpenoid analogues as potential anticancer agents. ChemMedChem 2013;8:812–18.
18. Xu W, Sun J, Zhang TT, et al. Pharmacokinetic behaviors and oral bioavailability of oridonin in rat plasma. Acta Pharmacol Sin 2006;27:1642–6.
19. Rao Vadaparthi PR, Pavan Kumar C, Kumar K, et al. Synthesis of costunolide derivatives by Pd-catalyzed Heck arylation and evaluation of their cytotoxic activities. Med Chem Res 2015;24:2871–8.
20. Zhang J, Ji F, Gu Y, et al. Chalcone derivatives as potent cell division cycle 25B phosphatase inhibitors. Pharmacol Rep 2014;66:515–19.
21. Coskun D, Erkisa M, Ulukaya E, et al. Novel hybrids of natural oridonin: synthesis and their antitumor biological evaluation. J Med Chem 2013;64:215–22.
22. Patrick TB, Agboka TY, Gorrell K. Heck reaction with 3-fluoro-4-bromo-3-buten-2-one. J Fluorine Chem 2008;129:983–993.
23. Liu CF, Shen QK, Li JJ, et al. Synthesis and biological evaluation of novel 3-substituted 4-anilino-coumarin and dihydropyran derivatives. Bioorg Med Chem 2017;32:1111–19.
24. Zhou HY, Dong FQ, Du XL, et al. Antitumor activities of bis-triazole moieties as potent cytotoxic agents. J Enzyme Inhib Med Chem 2016;31:283–91.
25. Luo GS, Muyaba M, Lyu W, et al. Design, synthesis and biological evaluation of novel 3-substituted 4-anilino-coumarin derivatives as antitumor agents. Bioorg Med Chem Lett 2017;27:867–74.